









市場行情
/
股票
/
nasdaq-prok
/

ProKidney Corp

PROK

2.530USD

-0.040-1.56%

收盤 12/26, 16:00（美東）報價延遲15分鐘

344.02M總市值

虧損本益比TTM



ProKidney Corp

2.530

-0.040-1.56%

概覽公司財務分析

概覽

公司

財務

分析

關於 ProKidney Corp 公司

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

ProKidney Corp簡介



公司代碼PROK

公司名稱ProKidney Corp

上市日期Jun 30, 2021

CEOCulleton (Bruce)

員工數量204

證券類型Ordinary Share

年結日Jun 30

公司地址2000 Frontis Plaza Blvd

城市WINSTON-SALEM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編27103

電話13369997028

網址https://prokidney.com/

公司代碼PROK

上市日期Jun 30, 2021

CEOCulleton (Bruce)

ProKidney Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

Mr. Ethan Holdaway

Investor Relations

Mr. William F. (Bill) Doyle

Independent Director

Mr. Pablo Legorreta

Chairman of the Board

Dr. Uma Sinha, Ph.D.

Independent Director

Mr. James Coulston, CPA

Chief Financial Officer

Ms. Jennifer Fox

Independent Director

Dr. Alan M. Lotvin, M.D.

Independent Director

Dr. Darin J. Weber, Ph.D.

Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial

Dr. Brian J. G. Pereira, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

Mr. Ethan Holdaway

Investor Relations

Mr. William F. (Bill) Doyle

Independent Director

Mr. Pablo Legorreta

Chairman of the Board

Dr. Uma Sinha, Ph.D.

Independent Director

Mr. James Coulston, CPA

Chief Financial Officer

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Tolerantia LLC

15.98%

Suvretta Capital Management, LLC

8.72%

Control Empresarial de Capitales, S.A. de C.V.

7.58%

Morgan Stanley Investment Management Inc. (US)

4.53%

BlackRock Mexico Operadora SA de CV SOFI

2.42%

其他

60.77%

持股股東

佔比

Tolerantia LLC

15.98%

Suvretta Capital Management, LLC

8.72%

Control Empresarial de Capitales, S.A. de C.V.

7.58%

Morgan Stanley Investment Management Inc. (US)

4.53%

BlackRock Mexico Operadora SA de CV SOFI

2.42%

其他

60.77%

股東類型

持股股東

佔比

Corporation

23.56%

Hedge Fund

11.03%

Investment Advisor

9.77%

Investment Advisor/Hedge Fund

6.08%

Individual Investor

1.83%

Research Firm

0.90%

Endowment Fund

0.71%

Bank and Trust

0.03%

Family Office

0.02%

其他

46.07%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

180

38.60M

28.59%

-15.99M

2025Q2

187

92.52M

71.43%

-12.19M

2025Q1

188

90.99M

70.46%

-13.35M

2024Q4

184

92.39M

74.12%

+21.48M

2024Q3

176

90.75M

73.53%

+26.28M

2024Q2

216

81.85M

70.67%

+19.77M

2024Q1

231

37.73M

58.52%

-31.32M

2023Q4

239

39.92M

63.74%

-31.95M

2023Q3

236

64.28M

104.12%

-21.16M

2023Q2

223

59.02M

95.83%

-21.49M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Tolerantia LLC

22.62M

16.75%

Jun 03, 2025

Suvretta Capital Management, LLC

12.34M

9.14%

Jun 30, 2025

Control Empresarial de Capitales, S.A. de C.V.

10.72M

7.94%

+2.28M

+27.04%

Apr 22, 2025

Morgan Stanley Investment Management Inc. (US)

5.71M

4.23%

-4.33M

-43.14%

Jun 30, 2025

BlackRock Mexico Operadora SA de CV SOFI

3.43M

2.54%

Aug 31, 2025

Operadora de Fondos GBM S.A.B. de C.V.

2.45M

1.81%

Aug 31, 2025

Bleichroeder LP

2.00M

1.48%

Jun 30, 2025

The Vanguard Group, Inc.

1.57M

1.16%

-3.64M

-69.92%

Jun 30, 2025

Culleton (Bruce)

1.54M

1.14%

+1.54M

Mar 17, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Schwab U.S. Small-Cap ETF

0.01%

ALPS Medical Breakthroughs ETF

Global X Russell 2000 Covered Call ETF

Schwab U.S. Broad Market ETF

ProShares UltraPro Russell2000

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

Avantis US Equity ETF

Global X Russell 2000 ETF

iShares Russell 2000 Growth ETF

Schwab U.S. Small-Cap ETF

佔比0.01%

ALPS Medical Breakthroughs ETF

佔比0%

Global X Russell 2000 Covered Call ETF

佔比0%

Schwab U.S. Broad Market ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

ProShares Hedge Replication ETF

佔比0%

iShares Russell 2000 ETF

佔比0%

Avantis US Equity ETF

佔比0%

Global X Russell 2000 ETF

佔比0%

iShares Russell 2000 Growth ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

ProKidney Corp的前五大股東是誰？



ProKidney Corp的前五大股東如下：
Tolerantia LLC
持有股份：22.62M
佔總股份比例：16.75%。
Suvretta Capital Management, LLC
持有股份：12.34M
佔總股份比例：9.14%。
Control Empresarial de Capitales, S.A. de C.V.
持有股份：10.72M
佔總股份比例：7.94%。
Morgan Stanley Investment Management Inc. (US)
持有股份：5.71M
佔總股份比例：4.23%。
BlackRock Mexico Operadora SA de CV SOFI
持有股份：3.43M
佔總股份比例：2.54%。